Copper Ions Bind to Two Sites on Somatostatin and Octreotide Peptides, Disrupting Their Shape and Biological Function | Research

The takeaway

Copper ions bind to two specific sites on the neuropeptide somatostatin and its clinical analog octreotide — one near the disulfide bond causing aggregation, another at the receptor-binding motif impairing biological activity.

2 binding sites
Distinct Cu(II) binding locations on somatostatin and octreotide — one causing aggregation, one impairing receptor binding

What the researchers found

Using transition metal ion FRET and native ion mobility-mass spectrometry, researchers identified two Cu(II) binding sites in both somatostatin (SST) and octreotide (OCT):

1. Near the disulfide bond — this site initiates self-aggregation of somatostatin, causing the peptide to clump and lose function

2. Complexed by two aromatic residues — this site directly affects the essential motif for receptor binding, impairing SST/OCT interaction with somatostatin receptors

Both binding sites were confirmed by collision-induced dissociation experiments. The structural changes upon copper binding affected both local conformation (FRET distances) and global peptide shape (ion mobility cross-sections).

Why it matters

Octreotide is one of the most important peptide drugs in clinical use, treating neuroendocrine tumors, acromegaly, and other conditions. Understanding how metal ions affect its structure and receptor binding is critical for drug formulation, storage, and efficacy. In the body, copper ions are present in the nervous system and could potentially modulate somatostatin signaling in ways that affect neurological and endocrine function. This has implications for both peptide pharmacology and understanding neuropeptide biology in health and disease.

How the study worked

Transition metal ion Förster resonance energy transfer (tmFRET) was used to measure intramolecular distances in somatostatin and octreotide in the presence and absence of Cu(II). Native ion mobility-mass spectrometry (IM-MS) provided global shape information for gas-phase peptide ions. Collision-induced dissociation (CID) confirmed binding site locations. The combination of local distance constraints (tmFRET) and global shape (IM-MS) provided comprehensive structural characterization.

What this study cannot tell us

The study primarily examined gas-phase peptide ions, which may not perfectly replicate solution-phase or in vivo conditions. The Cu(II) concentrations used may not reflect physiological copper levels. Functional biological assays (receptor binding, cellular responses) were not performed to quantify the impact of copper binding on actual biological activity. Only copper was studied as a metal ion — other biologically relevant metals (zinc, iron) may interact differently.

How to read the evidence

This is a high-quality analytical chemistry and structural biology study published in JACS (one of the top chemistry journals). The methodology is rigorous and the structural conclusions are well-supported, but functional biological validation is lacking.

When this study was published

Published in 2023, this study represents current advances in understanding metal-peptide interactions using cutting-edge mass spectrometry and FRET techniques.

The bigger picture

This study from the Journal of the American Chemical Society connects peptide structural biology to clinical pharmacology. Metal-peptide interactions are an underappreciated factor in neuropeptide function and drug design. The finding that copper can simultaneously cause aggregation (a stability problem) and impair receptor binding (an efficacy problem) has implications for peptide drug manufacturing, storage conditions, and potentially for understanding how trace metal dysregulation in neurological diseases might affect neuropeptide signaling.

Questions still open

Do physiological copper concentrations in the brain affect somatostatin signaling enough to have functional consequences?
Could copper chelation improve octreotide drug stability and receptor binding in pharmaceutical formulations?
Do other metal ions (zinc, iron, manganese) interact with somatostatin at similar or different binding sites?

Common questions

What is octreotide and why does its structure matter?

Octreotide is a synthetic peptide drug based on the natural brain hormone somatostatin. It's used to treat neuroendocrine tumors, acromegaly, and other conditions. Its shape determines how well it binds to receptors and works as a medication — so anything that alters its structure, like copper binding, could affect treatment efficacy.

How could copper ions affect brain peptides?

Copper is naturally present in the brain and is involved in many neurological processes. This study shows copper can bind to somatostatin at two sites: one causes the peptide to clump together, and another blocks the region that binds to receptors. This means copper fluctuations in the brain could potentially modulate somatostatin signaling.

Read the original research

The Structure of Cyclic Neuropeptide Somatostatin and Octapeptide Octreotide in the Presence of Copper Ions: Insights from Transition Metal Ion FRET and Native Ion Mobility-Mass Spectrometry.

Journal of the American Chemical Society, 145(19), 10542-10547

View on PubMed ↗Publisher’s paper ↗

Citation

Wu, Ri; Benzenberg, Lukas R; Svingou, Despoina; Zenobi, Renato. (2023). The Structure of Cyclic Neuropeptide Somatostatin and Octapeptide Octreotide in the Presence of Copper Ions: Insights from Transition Metal Ion FRET and Native Ion Mobility-Mass Spectrometry.. Journal of the American Chemical Society, 145(19), 10542-10547. https://doi.org/10.1021/jacs.2c13613